Physician profile
Tony Abbassi
NPI 1679589188
$598.71
in general payments reported to CMS, 2019-2025
9 companies · $57.21 in 2025
The $57.21 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.12 · 2020: $161 · 2021: $103 · 2022: $185 · 2023: $14.90 · 2025: $57.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $72.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $72.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $197.87 | 2021-2023 | Shingrix |
| Medtronic Vascular, INC. | $172.16 | 2019-2020 | |
| Pfizer INC. | $70.33 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $41.42 | 2021 | |
| Janssen Pharmaceuticals, INC | $37.89 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $21.83 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.90 | 2025 | Xifaxan |
| Dexcom, INC. | $19.79 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $17.52 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Abbassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.